Date: 2015-01-20
Type of information: Nomination
Compound:
Company: Affimed (Germany)
Therapeutic area: Cancer - Oncology
Type agreement: nomination
Action mechanism:
Disease:
Details: * On January, 20, 2015, Affimed, a clinical-stage biopharmaceutical company developing targeted cancer immunotherapies announced the appointment of Dr. Martin Treder as Chief Scientific Officer, effective January 1, 2015. Dr. Treder will lead Affimed’s ongoing efforts to further develop and utilize its proprietary biand trispecific TandAb platforms for the expansion of its internal pipeline and will provide scientific support for its clinical programs and for collaborations with corporate partners. Dr.Treder joins Affimed from CT Atlantic AG, a Swiss biotechnology company focused on the identification and development of human-derived monoclonal antibodies for the treatment of cancer. Dr. Eugene Zhukovsky, who had been Affimed’s Chief Scientific Officer since 2011, has left the company as of the end of 2014 to pursue other interests. Dr. Treder has 13 years of professional experience in the field of biotherapeutics research and development. Before joining Affimed, he was Chief Scientific Officer at CT Atlantic AG where he was responsible for establishing a broad research pipeline of various preclinical and clinical development programs. Prior to CT Atlantic, Dr. Treder held the position of Program Director at U3 Pharma AG, a German biotech company developing targeted cancer therapeutics, where he headed the company’s portfolio of innovative anti-HER3 therapeutic antibodies. Dr. Treder graduated with Honors from Monash University in Melbourne, Australia and obtained a diploma in Biology at the University of Würzburg, Germany. He earned his PhD working in Prof. Axel Ullrich\'s group at the Max Planck Institute of Biochemistry in Martinsried-Munich, receiving his doctorate from the Technical University of Munich, Germany.
Financial terms:
Latest news:
